Cargando…

Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab

Migraine is a highly disabling neurological condition, and preventative treatment still remains problematic, due to aspecificity of the majority of the currently available prophylactic drugs. Calcitonin-gene-related peptide (CGRP) plays a crucial role in migraine pathophysiology; agents aimed at blo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giamberardino, Maria Adele, Affaitati, Giannapia, Costantini, Raffaele, Cipollone, Francesco, Martelletti, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727105/ https://www.ncbi.nlm.nih.gov/pubmed/29263689 http://dx.doi.org/10.2147/JPR.S128143

Ejemplares similares

Impact of migraine on fibromyalgia symptoms
por: Giamberardino, Maria Adele, et al.
Publicado: (2016)

Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
por: Ornello, Raffaele, et al.
Publicado: (2020)

Effects of topical vs injection treatment of cervical myofascial trigger points on headache symptoms in migraine patients: a retrospective analysis
por: Affaitati, Giannapia, et al.
Publicado: (2018)

P003. NSAIDs for symptomatic treatment of headache
por: Affaitati, Giannapia, et al.
Publicado: (2015)

New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters?
por: Tana, Claudio, et al.
Publicado: (2013)

Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [Corrigendum]
Publicado: (2018)

Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
por: Ornello, Raffaele, et al.
Publicado: (2020)

Effects of PDE5 Inhibitors and sGC Stimulators in a Rat Model of Artificial Ureteral Calculosis
por: Sandner, Peter, et al.
Publicado: (2015)

Laparoscopic Cholecystectomy for Gallbladder Calculosis in Fibromyalgia Patients: Impact on Musculoskeletal Pain, Somatic Hyperalgesia and Central Sensitization
por: Costantini, Raffaele, et al.
Publicado: (2016)

Association between response to triptans and response to erenumab: real-life data
por: Frattale, Ilaria, et al.
Publicado: (2021)

Migraine induction with calcitonin gene-related peptide in patients from erenumab trials
por: Christensen, Casper Emil, et al.
Publicado: (2018)

Cranial autonomic symptoms and response to monoclonal antibodies targeting the Calcitonin gene-related peptide pathway: A real-world study
por: De Matteis, Eleonora, et al.
Publicado: (2022)

Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men
por: Ornello, Raffaele, et al.
Publicado: (2021)

Erenumab: A novel calcitonin gene-related peptide receptor antagonist developed specifically for migraine prevention
por: Garg, Shuchita, et al.
Publicado: (2020)

Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India
por: Chowdhury, Debashish, et al.
Publicado: (2022)

Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)
por: Martelletti, Paolo, et al.
Publicado: (2019)

Vascular safety of erenumab for migraine prevention
por: Kudrow, David, et al.
Publicado: (2020)

Early onset of efficacy with erenumab in patients with episodic and chronic migraine
por: Schwedt, Todd, et al.
Publicado: (2018)

Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
por: Alsaadi, Taoufik, et al.
Publicado: (2022)

Long‐term efficacy and safety during open‐label erenumab treatment in Japanese patients with episodic migraine
por: Sakai, Fumihiko, et al.
Publicado: (2021)

One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study
por: Goadsby, Peter J., et al.
Publicado: (2020)

The role of erenumab in the treatment of migraine
por: Andreou, Anna P., et al.
Publicado: (2020)

Common Clinical and Molecular Pathways between Migraine and Sarcoidosis
por: Tana, Claudio, et al.
Publicado: (2023)

A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults
por: Sakai, Fumihiko, et al.
Publicado: (2019)

Real-Life Analysis with Erenumab: First Target Therapy in the Episodic and Chronic Migraine’s Prophylaxis
por: Maraia, Zaira, et al.
Publicado: (2021)

Efficacy and safety of erenumab in women with a history of menstrual migraine
por: Pavlovic, Jelena M., et al.
Publicado: (2020)

Treatment with the monoclonal calcitonin gene‐related peptide receptor antibody erenumab: A real‐life study
por: de Vries Lentsch, Simone, et al.
Publicado: (2021)

Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes
por: De Matteis, Eleonora, et al.
Publicado: (2022)

Calcitonin Gene-Related Peptide Antagonists as a Savior in Episodic and Chronic Migraine: A Review
por: Pervez, Hira, et al.
Publicado: (2020)

Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 receptor
por: Hage La Cour, Sanne, et al.
Publicado: (2022)

Optimal Dose of Erenumab for Preventive Treatment of Episodic Migraine: A Systematic Review and Meta-Analysis
por: Yang, Yanbo, et al.
Publicado: (2022)

Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis
por: Kitamura, Shigekazu, et al.
Publicado: (2023)

Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials
por: Lampl, Christian, et al.
Publicado: (2022)

Assessment and characteristics of Erenumab therapy on migraine management
por: Saeed, Haitham, et al.
Publicado: (2022)

Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study
por: Ornello, Raffaele, et al.
Publicado: (2022)

Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study
por: Gladstone, Jonathan, et al.
Publicado: (2021)

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
por: Sacco, Simona, et al.
Publicado: (2019)

The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN)
por: Filippi, Massimo, et al.
Publicado: (2023)

Calcitonin gene-related peptide causes migraine aura
por: Al-Khazali, Haidar M., et al.
Publicado: (2023)

Nutrition and Calcitonin Gene Related Peptide (CGRP) in Migraine
por: Fila, Michal, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7dfd8pq8leec4v7ht5am1a5ge3